Abstract
The reference given as reference 1 was incorrect. It has now been corrected to: Fatma O, Emre B, Ertugrul Çagrı B, Gözde Kubra Y, Levent K. Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial, Rheumatology 2019, https://doi.org/10.1093/rheumatology/kez033.
Cite
CITATION STYLE
Sircar, G., Goswami, R. P., Sircar, D., Ghosh, A., & Ghosh, P. (2019, May 1). Corrigendum: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial: Reply (Rheumatology (2019) 58 (925-926) DOI: 10.1093/rheumatology/kez054). Rheumatology (United Kingdom). Oxford University Press. https://doi.org/10.1093/rheumatology/kez122
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
